drugset / Trial / NCT05084222

Use of Buventol Easyhaler and Bufomix Easyhaler in Methacoline Challenge Testing

NCT05084222

Phase 4 Completed 180 enrolled Orion Corporation, Orion Pharma
RandomizedParallel-groupOpen-labelTreatment

Summary

The study compares Buventol® Easyhaler® and Bufomix® Easyhaler® to the current standard treatment during methacholine challenge test. The trial will also provide inspiratory flow profile data for Easyhaler inhaler. This trial is designed to provide a further evidence for the use of Easyhaler in diagnostic bronchial challenge tests and on the use of Easyhaler inhaler during obstructive event.

Timeline

Start
2021-11-11
Primary completion
2023-06-30
Completion
2023-06-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Budesonide Small molecule 320 ug Inhaled
Subject Formoterol Other / unclassified 9 ug Inhaled
Subject Salbutamol Unknown 100 ug Inhaled
Subject Salbutamol Unknown 200 ug Inhaled

Indications